Adjuvant Therapy of Melanoma

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Adjuvant therapy for high-risk melanoma has been extensively studied.
• Previous regimens varied in dosage, administration route, formulation, and duration.
• High-dose regimen (HDI) demonstrated improvements in relapse-free survival (RFS) and overall survival (OS).

Purpose of the Study:

• To review the efficacy and safety of various adjuvant therapies for high-risk melanoma.
• To compare ipilimumab regimens and contrast them with newer treatment standards.
• To highlight the evolution of melanoma adjuvant therapy.

Main Methods:

• Review of clinical trials investigating adjuvant therapies for high-risk melanoma.
• Analysis of data on relapse-free survival (RFS) and overall survival (OS).
• Comparison of different ipilimumab dosages and newer immunotherapies/targeted therapies.

Main Results:

• High-dose ipilimumab (HDI) showed significant RFS and OS benefits in multiple trials.
• Ipilimumab at 3 mg/kg offered significant OS benefits over HDI with reduced toxicity.
• Nivolumab, pembrolizumab, and BRAF-MEK inhibitors are now standard of care due to superior RFS and safety.

Conclusions:

• Adjuvant therapy for high-risk melanoma has evolved significantly.
• Ipilimumab demonstrated efficacy, but newer agents offer improved risk-benefit profiles.
• Current standards of care prioritize nivolumab, pembrolizumab, and targeted BRAF-MEK inhibitors for better patient outcomes.